Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:937-942

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yasunari, K.
Right arrow Articles by Yoshikawa, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yasunari, K.
Right arrow Articles by Yoshikawa, J.
Related Collections
Right arrow Cell signalling/signal transduction
Right arrow Oxidant stress
Right arrow Mechanism of atherosclerosis/growth factors
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:937.)
© 2001 American Heart Association, Inc.


Vascular Biology

HMG-CoA Reductase Inhibitors Prevent Migration of Human Coronary Smooth Muscle Cells Through Suppression of Increase in Oxidative Stress

Kenichi Yasunari; Kensaku Maeda; Mieko Minami; Junichi Yoshikawa

From the Department of Cardiology, Graduate School of Medicine, Osaka City University, Osaka, Japan.

Correspondence to Kenichi Yasunari, MD, Department of Cardiology, Graduate School of Medicine, Osaka City University, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. E-mail yasunari{at}osaka.med.or.jp

Abstract—In vitro and in vivo evidence of a decrease in vascular smooth muscle cell (SMC) migration induced by 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors has been reported. When added to SMC cultures for 6 hours, the HMG-CoA reductase inhibitors fluvastatin, simvastatin, and pravastatin at 1 µmol/L resulted in a 48%, 50%, and 16% suppression, respectively, of human coronary SMC migration; these reductions mirrored the suppression in oxidative stress induced by 1 µmol/L lysophosphatidylcholine (lyso-PC) of 50%, 53% and 19%, respectively. The hydroxylated metabolites of fluvastatin, M2 and M3, at 1 µmol/L also suppressed the enhancement of SMC migration by 58% and 45% and the increase in oxidative stress induced by lyso-PC of 58% and 49%, respectively. Lyso-PC activated phospholipase D and protein kinase C (PKC), and this activation was also suppressed by HMG-CoA reductase inhibitors. The inhibition of phospholipase D and PKC was reversed by 100 µmol/L mevalonate, its isoprenoid derivative, farnesol, and geranylgeraniol but not by 10 µmol/L squalene. Antisense oligodeoxynucleotides at 5 µmol/L to PKC-{alpha}, but not those to the PKC-ß isoform, suppressed the lyso-PC–mediated increases in SMC migration and oxidative stress. These findings suggest that HMG-CoA reductase inhibitors have direct antimigratory effects on the vascular wall beyond their effects on plasma lipids and that they might exert such antimigratory effects via suppression of the phospholipase D– and PKC (possibly PKC-{alpha})-induced increase in oxidative stress, which might in turn prevent significant coronary artery disease.


Key Words: lipids • atherosclerosis • smooth muscle • coronary disease




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
B. Ky, A. Burke, S. Tsimikas, M. L. Wolfe, M. G. Tadesse, P. O. Szapary, J. L. Witztum, G. A. FitzGerald, and D. J. Rader
The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans
J. Am. Coll. Cardiol., April 29, 2008; 51(17): 1653 - 1662.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
R. E. Girgis, S. Mozammel, H. C. Champion, D. Li, X. Peng, L. Shimoda, R. M. Tuder, R. A. Johns, and P. M. Hassoun
Regression of chronic hypoxic pulmonary hypertension by simvastatin
Am J Physiol Lung Cell Mol Physiol, May 1, 2007; 292(5): L1105 - L1110.
[Abstract] [Full Text] [PDF]


Home page
VASC ENDOVASCULAR SURGHome page
S. L. Bledsoe, J. C. Barr, R. T. Fitzgerald, A. T. Brown, F. H. Faas, J. F. Eidt, and M. M. Moursi
Pravastatin and Clopidogrel Combined Inhibit Intimal Hyperplasia in a Rat Carotid Endarterectomy Model
Vascular and Endovascular Surgery, January 1, 2006; 40(1): 49 - 57.
[Abstract] [PDF]


Home page
Endocr Relat CancerHome page
W-B Zhong, Y-C Liang, C-Y Wang, T-C Chang, and W-S Lee
Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling
Endocr. Relat. Cancer, September 1, 2005; 12(3): 615 - 629.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
M. Campbell, W. E. Allen, C. Sawyer, B. Vanhaesebroeck, and E. R. Trimble
Glucose-Potentiated Chemotaxis in Human Vascular Smooth Muscle Is Dependent on Cross-Talk Between the PI3K and MAPK Signaling Pathways
Circ. Res., August 20, 2004; 95(4): 380 - 388.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
K. Yasunari, K. Maeda, M. Nakamura, and J. Yoshikawa
Oxidative Stress in Leukocytes Is a Possible Link Between Blood Pressure, Blood Glucose, and C-Reacting Protein
Hypertension, March 1, 2002; 39(3): 777 - 780.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
D. D. Gutterman
Vascular Dysfunction in Hyperglycemia: Is Protein Kinase C the Culprit?
Circ. Res., January 11, 2002; 90(1): 5 - 7.
[Full Text] [PDF]